PLN 35.0
(4.17%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 15.47 Million PLN | 202.96% |
2022 | 5.1 Million PLN | 18.87% |
2021 | 4.29 Million PLN | 204.32% |
2020 | 1.41 Million PLN | 56.54% |
2019 | 902 Thousand PLN | -21.9% |
2018 | 1.15 Million PLN | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 3.13 Million PLN | -34.92% |
2024 Q2 | 3.86 Million PLN | 26.79% |
2023 Q2 | 4.2 Million PLN | 92.14% |
2023 Q4 | 4.81 Million PLN | 13.1% |
2023 FY | 15.47 Million PLN | 202.96% |
2023 Q1 | 2.18 Million PLN | 24.8% |
2023 Q3 | 4.26 Million PLN | 1.31% |
2022 FY | 5.1 Million PLN | 18.87% |
2022 Q4 | 1.75 Million PLN | 31.09% |
2022 Q3 | 1.33 Million PLN | 52.22% |
2022 Q2 | 879 Thousand PLN | -22.69% |
2022 Q1 | 1.13 Million PLN | -51.31% |
2021 Q1 | 335 Thousand PLN | -13.66% |
2021 FY | 4.29 Million PLN | 204.32% |
2021 Q4 | 2.33 Million PLN | 120.49% |
2021 Q3 | 1.05 Million PLN | 86.44% |
2021 Q2 | 568 Thousand PLN | 69.55% |
2020 Q2 | 229.5 Thousand PLN | 0.0% |
2020 Q3 | 385 Thousand PLN | 67.76% |
2020 Q4 | 388 Thousand PLN | 0.78% |
2020 FY | 1.41 Million PLN | 56.54% |
2020 Q1 | 229.5 Thousand PLN | 0.0% |
2019 FY | 902 Thousand PLN | -21.9% |
2018 FY | 1.15 Million PLN | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Bioceltix S.A. | 15.38 Million PLN | -0.587% |
BIOTON S.A. | 57.55 Million PLN | 73.114% |
Captor Therapeutics Spolka Akcyjna | 79.91 Million PLN | 80.636% |
Mabion S.A. | 59.52 Million PLN | 74.001% |
Molecure S.A. | 31.73 Million PLN | 51.23% |
NanoGroup S.A. | 7.82 Million PLN | -97.722% |
Pharmena S.A. | -32.76 Million PLN | 147.23% |
Pure Biologics Spólka Akcyjna | 29.14 Million PLN | 46.902% |
Ryvu Therapeutics S.A. | 4.73 Million PLN | -226.615% |
Synthaverse S.A. | 26.35 Million PLN | 41.28% |
Urteste S.A. | 5.96 Million PLN | -159.3% |